Blinatumomab: A Bispecific T Cell Engager (Bite) Antibody Against CD19/CD3 for Refractory Acute Lymphoid Leukemia

Authors

Jingjing Wu, Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Jiaping Fu, Department of Hematology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
Mingzhi Zhang, Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Delong Liu, Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Delong_liu@nymc.edu.

Author Type(s)

Faculty

DOI

10.1186/s13045-015-0195-4

Journal Title

Journal of Hematology & Oncology

First Page

104

Document Type

Article

Publication Date

9-4-2015

Abstract

Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia.

Recommended Citation

Wu, J., Fu, J., Zhang, M., & Liu, D. (2015). Blinatumomab: A Bispecific T Cell Engager (Bite) Antibody Against CD19/CD3 for Refractory Acute Lymphoid Leukemia. Journal of Hematology & Oncology, 8, 104. https://doi.org/10.1186/s13045-015-0195-4